18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Sponsor
- Peking University Cancer Hospital & Institute
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- 2 year progression-free survival
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of diffuse large B-cell lymphoma can predict disease progression
Detailed Description
In this study investigators develop a prognostic model based on 18F-FDG PET/CT and test its ability for prognostic value in patients with DLBCL. PET/CT scans evaluation using the liver SUVmax as reference. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold (1.6 fold of liver SUVmax) or new 18F-FDG avid lesions. 18F-FDG PET/CT-based prognostic model includes PET/CT image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in DLBCL.
Investigators
Xuejuan Wang,MD
Department of Nuclear Medicine
Peking University Cancer Hospital & Institute
Eligibility Criteria
Inclusion Criteria
- •newly diagnosed DLBCL;
- •treated using an anthracycline-containing regimen with or without rituximab;
- •minimal follow-up at 6 months after the completion of first-line treatment;
- •complete medical history and clinicopathological data
Exclusion Criteria
- •secondary malignant disease;
- •serious infection or inflammation (e.g., HIV);
- •primary central nervous system lymphoma;
- •hepatic or renal dysfunction.
Outcomes
Primary Outcomes
2 year progression-free survival
Time Frame: up to 2 years after initial diagnosis